We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00922727
Recruitment Status : Completed
First Posted : June 17, 2009
Last Update Posted : January 25, 2018
Sponsor:
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
J. Marc Rhoads, The University of Texas Health Science Center, Houston

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the safety and tolerability of the probiotic Lactobacillus reuteri (LR) in healthy adult patients. Patients will be randomized to receive either LR or placebo orally each day for a total of 60 doses. The effects on fecal bacteria, circulating white blood cell receptors and inflammatory cytokine profiles will be measured.

Condition or disease Intervention/treatment Phase
Colic Gastrointestinal Tract Infections Biological: L. reuteri Biological: Sunflower Oil Phase 1

Detailed Description:
Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract micro flora and prevention and treatment of mild diarrhea associated with GI-tract infections. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938. The patients will receive 5 drops (10^8 live organisms) by mouth daily for 60 days. Daily administration will include 5 drops (5x10^8) of L. reuteri or placebo daily for two months. During this time,circulating peripheral blood mononuclear cell (PBMC) toll-like receptor-2 and -4 levels will be measured, along with PBMC cytokine production levels in vitro. Fecal DGGE analysis(with sequencing of bacterial rDNA) will be completed identifying changes in fecal microbiota. Inflammation in the gut will also be assessed by fecal calprotectin assay (ELISA). The time on study treatment is 2 months, with 4 months observation, for a total of 6 months. There will be 7 required visits, during which, we will assess safety and immune system effects.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase I Safety and Tolerance of Lactobacillus Reuteri in Adults
Study Start Date : October 2009
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: L. reuteri
Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
 Biological: L. reuteri
The oil drops contains 10^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10^8 CFU/ 5 drops and less than 8 x 10^8 CFU/ 5 drops.
Other Name: BioGaia Drops
Placebo Comparator: Sunflower Oil
Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
 Biological: Sunflower Oil
As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops.
Other Name: Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Treatment of adults with probiotic (health-promoting bacteria) LR, will be safe and well-tolerated. [ Time Frame: 8/1/2009 - 7/1/2009 ]

Secondary Outcome Measures :
  1. Determine if LR treatment affects circulating levels of pro-inflammatory and anti-inflammatory cytokines, along with expression levels of toll like receptors (TLRs)-2 and -4 in circulating peripheral blood mononuclear cells. [ Time Frame: 4/1/2009-7/1/2009 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Adults (18 - 60 years old)
  • No other recognized illness

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Patient taking immunosuppressive medications, including oral corticosteroids
  • Positive result of HIV, Hepatitis B, and/or Hepatitis C test
  • Abnormal lab test results
  • Gastrointestinal related diseases and surgeries
  • Patients with an allergy to antibiotics
  • Presence of fever or a pre-existing adverse event monitored in the study
  • No more than two study participants in one household
  • Use of probiotics in the last 90 days
  • Diarrheal illness within the past 30 days
  • Recent or current use of oral antibiotics /anti-fungals(in the past 2 weeks)
  • Current use of oral laxatives
  • Chronic alcohol use or more than 1 drink per day
  • Subjects with implanted prosthetic devices including prosthetic heart valves
  • Known sensitivity to sunflower oil or products containing linolenic/oleic acids
  • Will require that subject not take any other probiotic-containing products, including yogurt supplemented with probiotics during the 6-month period
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00922727


Locations
Layout table for location information
United States, Texas
University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
National Center for Complementary and Integrative Health (NCCIH)
Investigators
Layout table for investigator information
Principal Investigator: J. Marc Rhoads, M.D. The University of Texas Health Science Center, Houston
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: J. Marc Rhoads, Director of Pediatric Gastroenterology, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00922727    
Other Study ID Numbers: HS-MSC-08-0266
R21AT003519-01A2 ( U.S. NIH Grant/Contract )
U01AT003519 ( U.S. NIH Grant/Contract )
First Posted: June 17, 2009    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Keywords provided by J. Marc Rhoads, The University of Texas Health Science Center, Houston:
L. reuteri
Cytokines
Toll like receptors
Healthy Adults
Probiotics